Extended release tablet formulations of flibanserin and method for manufacturing the same

US8658207B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Wolfram EISENREICH · Ulm, DE
• Thomas Friedl · Seekirchen am Wallersee, AT
• Florian SOMMER · Leutkirch im Allgäu, DE
• Nantharat Pearnchob · Biberach, DE
• Karl Gerhard WAGNER · Biberach, DE

Key dates

• Filing date: Aug 13, 2007
• Grant date: Feb 25, 2014
• Expiry date: Dec 20, 2029

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/28
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of flibanserin and at least one pharmaceutically acceptable excipient, characterized in that said pharmaceutical release systems exhibit a pharmacokinetic profile that is characterized by an average maximum flibanserin plasma concentration Cmax lower than 300 ng/mL, preferably lower than 200 ng/mL after administration of a single dose to healthy volunteers in fasted state or directly after a meal.